Loading
Life sciences · Journal article
Journal of Visualized Experiments · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This single-center retrospective study analyzed de-duplicated Pseudomonas aeruginosa isolates collected at Huaian Municipal Infectious Diseases Hospital from 2023 to 2025. A total of 121 unique isolates were included, of which 83.5% were from sputum. Antimicrobial susceptibility testing (AST) was performed using an automated microbiology system, and minimum inhibitory concentration (MIC) results were interpreted according to CLSI M100, 33rd edition. In early 2024, a four-dimensional linkage-targeted antimicrobial stewardship intervention was implemented in the Respiratory and Tuberculosis Department (Resp-TB) (n = 97), comprising: (1) dynamic antimicrobial resistance surveillance with quarterly feedback; (2) risk-stratified antimicrobial prescribing based on local susceptibility data; (3) standardized specimen collection protocols; and (4) enhanced infection prevention and control measures. In the Resp-TB, the overall resistance rates were 74.19% in 2023, 81.63% in 2024, and 82.93% in 2025, with no significant reduction after the intervention (p ≈ 0.37). By 2025, resistance to tobramycin was 0/41 (0.00%), cefepime was 1/41 (2.44%), and piperacillin-tazobactam was 0/41 (0.00%); levofloxacin resistance reached 15/41 (36.59%). Trimethoprim-sulfamethoxazole resistance remained high across the study period. These findings show persistent antimicrobial resistance in the Resp-TB after implementation of the intervention, while resistance to selected agents, including tobramycin, cefepime, and piperacillin-tazobactam, remained low in 2025.